GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles

Summary

GenScript Biotech reported first-half 2026 revenue of US$404.2 million with 27.3% growth on a comparable basis, while adjusted net profit surged 203.3%. The company's AI drug discovery business doubled during the period, with Gene-to-Protein generating two-thirds of GenScript Life Science Group revenue.